72 related articles for article (PubMed ID: 1776863)
1. Cytotoxic activity of synthetic aza alkyl lysophospholipids against drug sensitive and drug resistant human tumor cell lines.
Morimoto H; Broquet C; Principe P; Mencia-Huerta JM; Braquet P; Bonavida B
Anticancer Res; 1991; 11(6):2223-9. PubMed ID: 1776863
[TBL] [Abstract][Full Text] [Related]
2. Preferential induction of TNF-alpha and IL-1beta and inhibition of IL-10 secretion by human peripheral blood monocytes by synthetic aza-alkyl lysophospholipids.
Gan XH; Bonavida B
Cell Immunol; 1999 May; 193(2):125-33. PubMed ID: 10222054
[TBL] [Abstract][Full Text] [Related]
3. Cytotoxicity of new aza-alkyl lysophospholipids against drug-sensitive and resistant human ovarian tumor-cell lines - role of free-radicals and potentiation of cytotoxicity by tnf-alpha and cddp.
Hourizadeh A; Broquet C; Menciahuerta J; Braquet P; Berek J; Bonavida B
Oncol Rep; 1994 Nov; 1(6):1253-9. PubMed ID: 21607526
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effect of tumor necrosis factor-alpha- and diphtheria toxin-mediated cytotoxicity in sensitive and resistant human ovarian tumor cell lines.
Morimoto H; Safrit JT; Bonavida B
J Immunol; 1991 Oct; 147(8):2609-16. PubMed ID: 1918981
[TBL] [Abstract][Full Text] [Related]
5. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of human ovarian tumor cells by subtoxic CDDP to anti-fas antibody-mediated cytotoxicity and apoptosis.
Uslu R; Jewett A; Bonavida B
Gynecol Oncol; 1996 Aug; 62(2):282-91. PubMed ID: 8751562
[TBL] [Abstract][Full Text] [Related]
7. Effects of thaliblastine on cytotoxicity and DNA damage in drug-sensitive and -resistant rat ovarian tumor cells treated with cisplatin.
Chen G; Zeller WJ
Anticancer Res; 1993; 13(1):219-23. PubMed ID: 8476216
[TBL] [Abstract][Full Text] [Related]
8. The primary in vitro anticancer activity of "half-mustard type" phenothiazines in NCI's revised anticancer screening paradigm.
Wuonola MA; Palfreyman MG; Motohashi N; Kawase M; Gabay S; Gupta RR; Molnár J
Anticancer Res; 1998; 18(1A):337-48. PubMed ID: 9568100
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents.
Berger B; Marquardt H; Westendorf J
Cancer Res; 1996 May; 56(9):2094-104. PubMed ID: 8616856
[TBL] [Abstract][Full Text] [Related]
10. Overcoming tumor necrosis factor and drug resistance of human tumor cell lines by combination treatment with anti-Fas antibody and drugs or toxins.
Morimoto H; Yonehara S; Bonavida B
Cancer Res; 1993 Jun; 53(11):2591-6. PubMed ID: 7684321
[TBL] [Abstract][Full Text] [Related]
11. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
12. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
13. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
14. Transport of cisplatin and bis-acetato-ammine-dichlorocyclohexylamine Platinum(IV) (JM216) in human ovarian carcinoma cell lines: identification of a plasma membrane protein associated with cisplatin resistance.
Sharp SY; Rogers PM; Kelland LR
Clin Cancer Res; 1995 Sep; 1(9):981-9. PubMed ID: 9816070
[TBL] [Abstract][Full Text] [Related]
15. Chemosensitization of human prostate carcinoma cell lines to anti-fas-mediated cytotoxicity and apoptosis.
Uslu R; Borsellino N; Frost P; Gárban H; Ng CP; Mizutani Y; Belldegrun A; Bonavida B
Clin Cancer Res; 1997 Jun; 3(6):963-72. PubMed ID: 9815772
[TBL] [Abstract][Full Text] [Related]
16. Effect of recombinant human TNF on human ovarian cancer cell lines.
Vigani A; Miglietta L; Chiara S; Repetto L; Pichi E; Cimoli G; Morelli L; Poggi L; Billi G; Parodi S
Boll Soc Ital Biol Sper; 1990 Jun; 66(6):537-42. PubMed ID: 2257120
[TBL] [Abstract][Full Text] [Related]
17. In vitro characterization of the anticancer activity of membrane-active cationic peptides. I. Peptide-mediated cytotoxicity and peptide-enhanced cytotoxic activity of doxorubicin against wild-type and p-glycoprotein over-expressing tumor cell lines.
Johnstone SA; Gelmon K; Mayer LD; Hancock RE; Bally MB
Anticancer Drug Des; 2000 Apr; 15(2):151-60. PubMed ID: 10901303
[TBL] [Abstract][Full Text] [Related]
18. Natural killer-sensitive targets stimulate production of TNF-alpha but not TNF-beta (lymphotoxin) by highly purified human peripheral blood large granular lymphocytes.
Peters PM; Ortaldo JR; Shalaby MR; Svedersky LP; Nedwin GE; Bringman TS; Hass PE; Aggarwal BB; Herberman RB; Goeddel DV
J Immunol; 1986 Oct; 137(8):2592-8. PubMed ID: 3760569
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxicity of alkyl-lysophospholipid derivatives and low-alkyl-cleavage enzyme activities in rat brain tumor cells.
Berdel WE; Greiner E; Fink U; Stavrou D; Reichert A; Rastetter J; Hoffman DR; Snyder F
Cancer Res; 1983 Feb; 43(2):541-5. PubMed ID: 6848177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
